An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma

Investigational New Drugs

Volumn 30, Issue 1, 2012, Pages 387-394

  Kim, George P ^a   Mahoney, Michelle R ^b   Szydlo, Daniel ^b   Mok, Tony S K ^c   Marshke, Robert ^d   Holen, Kyle ^e   Picus, Joel ^f   Boyer, Michael ^g   Pitot, Henry C ^b   Rubin, Joseph ^b   Philip, Philip A ^h   Nowak, Anna ⁱ   Wright, John J ^j   Erlichman, Charles ^b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC ROCHESTER   (United States)

^c NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF WISCONSIN   (United States)

^f WASHINGTON UNIVERSITY   (United States)

^g ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^h KARMANOS CANCER INSTITUTE   (United States)

ⁱ SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^j NATIONAL CANCER INSTITUTE   (United States)

more..

Author keywords

Antineoplastic agents; Biologic agents; Boronic acids; Treatment outcome

Indexed keywords

BORTEZOMIB;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EVALUATION; COGNITIVE DEFECT; CONTROLLED STUDY; DESQUAMATION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HIP PAIN; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPONATREMIA; HYPOTENSION; ILEUS; LIVER CELL CARCINOMA; LIVER FAILURE; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ASIA; BORONIC ACIDS; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NORTH AMERICA; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84856554756     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9532-1     Document Type: Article

References (31)

1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74-108 (Pubitemid 40372904)
2. El-Serag HB, Mason AC (1999) Rising incidence of hepatocellular carcinoma in the united states. N Engl J Med 340(10):745-750. doi:10.1056/ nejm199903113401001 (Pubitemid 29114292)
3. El-Serag HB (2007) Epidemiology of hepatocellular carcinoma in USA. Hepatol Res 37(Suppl 2):S88-94
4. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB (2006) Phase ii study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24(26):4293-4300 (Pubitemid 46630787)
5. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378-390
6. Cheng A, Kang Y, Chen Z, Tsao C, Qin S, Kim J, Burock K, Zou J, Voliotis D, Guan ZZ (2008) Randomized phase iii trial of sorafenib versus placebo in asian patients with advanced hepatocellular carcinoma. J Clin Oncol (Meeting Abstracts) 26(15-suppl):4509
7. Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J (1999) The proteasome inhibitor ps-341 in cancer therapy. Clin Cancer Res 5(9):2638-2645 (Pubitemid 29437352)
8. Rolfe M, Chiu MI, Pagano M (1997) The ubiquitin-mediated proteolytic pathway as a therapeutic area. J Mol Med 75(1):5-17 (Pubitemid 27067134)
9. Ciechanover A, Orian A, Schwartz AL (2000) Ubiquitin-mediated proteolysis: Biological regulation via destruction. Bioessays 22(5):442-451 (Pubitemid 30308270)
10. Ozturk M (1999) Genetic aspects of hepatocellular carcinogenesis. Semin Liver Dis 19(3):235-242 (Pubitemid 29488766)
11. Wang XW, Forrester K, Yeh H, Feitelson MA, Gu JR, Harris CC (1994) Hepatitis b virus x protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ercc3. Proc Natl Acad Sci USA 91(6):2230-2234 (Pubitemid 24092077)
12. Ray RB, Steele R, Meyer K, Ray R (1997) Transcriptional repression of p53 promoter by hepatitis c virus core protein. J Biol Chem 272(17):10983-10986 (Pubitemid 27184081)
13. Frankel A, Man S, Elliott P, Adams J, Kerbel RS (2000) Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor ps-341. Clin Cancer Res 6(9):3719-3728
14. Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl Bancroft C, Sausville E, Adams J, Elliott P, Van Waes C (2001) Novel proteasome inhibitor ps-341 inhibits activation of nuclear factorkappa b, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 7(5):1419-1428 (Pubitemid 32708698)
15. Cusack JC Jr, Liu R, Houston M, Abendroth K, Elliott PJ, Adams J, Baldwin AS Jr (2001) Enhanced chemosensitivity to cpt-11 with proteasome inhibitor ps-341: Implications for systemic nuclear factor-kappab inhibition. Cancer Res 61(9):3535-3540 (Pubitemid 32694955)
16. Bold RJ, Virudachalam S, McConkey DJ (2001) Chemosensitization of pancreatic cancer by inhibition of the 26s proteasome. J Surg Res 100(1):11-17 (Pubitemid 32802698)
17. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos M-V, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG, The VTI (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359(9):906-917. doi:10.1056/NEJMoa0801479
18. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348(26):2609-2617 (Pubitemid 36741588)
19. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the united states, national cancer institute of canada. J Natl Cancer Inst 92(3):205-216
20. Simon R (1989) Optimal two-stage designs for phase ii clinical trials. Control Clin Trials 10(1):1-10 (Pubitemid 19099520)
21. Duffy D, Santner T (1987) Confidence intervals for a binomial parameter based on multistage tests. Biometrics 43:81-93 (Pubitemid 17063894)
22. Kaplan MP (1958) Nonparametirc estimation for incomplete observations. J Am Stat Assoc 53:457-481
23. Chang L, Kamata H, Solinas G, Luo J-L, Maeda S, Venuprasad K, Liu Y-C, Karin M (2006) The e3 ubiquitin ligase itch couples jnk activation to tnf[alpha]-induced cell death by inducing c-flipl turnover. Cell 124(3):601-613 (Pubitemid 43199444)
24. Anan A, Baskin-Bey ES, Isomoto H, Mott JL, Bronk SF, Albrecht JH, Gores GJ (2006) Proteasome inhibition attenuates hepatic injury in the bile duct-ligated mouse. Am J Physiol Gastrointest Liver Physiol 291(4):G709-716. doi:10.1152/ajpgi.00126.2006 (Pubitemid 44511688)
25. Davis NB, Taber DA, Ansari RH, Ryan CW, George C, Vokes EE, Vogelzang NJ, Stadler WM (2004) Phase ii trial of ps-341 in patients with renal cell cancer: A university of chicago phase ii consortium study. J Clin Oncol 22(1):115-119. doi:10.1200/ jco.2004.07.165 (Pubitemid 41095122)
26. Engel RH, Brown JA, Von Roenn JH, O'Regan RM, Bergan R, Badve S, Rademaker A, Gradishar WJ (2007) A phase ii study of single agent bortezomib in patients with metastatic breast cancer: A single institution experience. Cancer Investig 25(8):733-737 (Pubitemid 350223168)
27. Mackay H, Hedley D, Major P, Townsley C, Mackenzie M, Vincent M, Degendorfer P, Tsao M-S, Nicklee T, Birle D, Wright J, Siu L, Moore M, Oza A (2005) A phase ii trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer. Clin Cancer Res 11(15):5526-5533. doi:10.1158/1078-0432.ccr-05-0081 (Pubitemid 41060829)
28. Kozuch PS, Rocha-Lima CM, Dragovich T, Hochster H, O'Neil BH, Atiq OT, Pipas JM, Ryan DP, Lenz H-J (2008) Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: Results from a randomized phase ii study. J Clin Oncol 26(14):2320-2326. doi:10.1200/jco.2007.14.0152
29. Alberts SR, Foster NR, Morton RF, Kugler J, Schaefer P, Wiesenfeld M, Fitch TR, Steen P, Kim GP, Gill S (2005) Ps-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: A north central cancer treatment group (ncctg) randomized phase ii study. Ann Oncol 16(10):1654-1661 (Pubitemid 41510140)
30. Hegewisch-Becker S, Sterneck M, Schubert U, Rogiers X, Guerciolini R, Pierce JE, Hossfeld DK (2004) Phase i/ii trial of bortezomib in patients with unresectable hepatocellular carcinoma (hcc). J Clin Oncol (Meeting Abstracts) 22 (14-suppl):4089
31. Berlin JD, Powell ME, Su Y, Horton L, Short S, Richmond A, Kauh JS, Staley CA, Mulcahy M, Benson AB, III (2008) Bortezomib (b) and doxorubicin (dox) in patients (pts) with hepatocellular cancer (hcc): A phase ii trial of the eastern cooperative oncology group (ecog 6202) with laboratory correlates. J Clin Oncol (Meeting Abstracts) 26 (15-suppl):4592